Navigation Links
Oramed's Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.
Date:12/21/2009

JERUSALEM, Israel, December 21 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that Dr Roy Eldor will present an overview of the clinical development of Oramed's Oral Insulin capsule. Dr. Eldor is the principal investigator for all of Oramed's clinical trials conducted at Hadassah Medical Center. He is a physician in the Diabetes Unit and Endocrinology Department of Hadassah Medical Center.

The conference will take place at the Wohl Center, Bar Ilan University, in Ramat Gan, Israel on December 21-23. Dr Eldor's presentation will be given on December 22 at 4:10 PM. He will be highlighting all of the clinical work that Oramed has completed to date, ranging from preclinical trials to its current Phase 2b trial.

"Oramed is honored to have been invited to present at this very important conference to share the clinical development of its Oral Insulin Capsule with the scientific community" says Dr Roy Eldor.

About the Conference:

The Conference will start to focus on the translation of "cutting edge" diabetes research into practical clinical care, with a particular emphasis on the organization and delivery of care in different health systems. Updates and overviews will be given by invited speakers from around the world, together with workshop and debate sessions and submitted oral and poster presentations.

For More information, please visit http://www.diabetescenter.org.il

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relations Contacts:

    Oramed Pharmaceuticals
    Tara Horn
    USA: +1-646-240-4193
    Int'l: +972-54-334-318
    Office: +972-2-566-0001
    Email: tara@oramed.com

SOURCE Oramed Pharmaceuticals Inc.


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mindray Medical to Exhibit at MEDICA 2009 in Dusseldorf, Germany
2. HCC Medical Insurance Services Selects Eldorado's Innovative Claims & Benefits Platform
3. Global Med Technologies(R) Licenses ElDorado(TM) Software Solutions to $3.5 Billion MedStar Health of Baltimore, MD
4. Global Med Technologies(R), Inc. Receives FDA 510(K) Clearance for ElDorado Donor(TM)
5. Global Med Technologies(R), Inc. Recieves FDA 510(K) Clearance for ElDorado Donor(TM)
6. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
7. IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care
8. Limeade Wellness Program Chosen to Serve Washington State Employees
9. Ten Finalists Chosen for Hutch Award(R)
10. M. D. Anderson team chosen to help navigate Cancer Genome Atlas
11. Michigan Dentist Chosen President-Elect of the American Dental Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... ... Chronic stress can have a silent, yet dangerous, impact on men’s heart ... increase inflammation, both of which raise the risk of heart attack and even stroke,” ... Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other issues that indirectly ...
(Date:5/5/2016)... Rochester, NY (PRWEB) , ... May 05, 2016 ... ... app is now available for iOS and Android devices. VisualDx is the ... expanded to include diagnostic support across general medicine. The system speeds diagnosis, ...
(Date:5/5/2016)... ... May 05, 2016 , ... CURE Media Group , ... announced a new collaboration with Imerman Angels to expand outreach and emotional ... world. , “Imerman Angels provides an emotional lifeline to patients and families facing the ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... If you ... stretch marks on your skin, you may want to consider a treatment that some ... of Advanced Dermatology P.C. , Microneedling, also known as skin needling, is ...
(Date:5/5/2016)... Ill. (PRWEB) , ... May 05, 2016 , ... Dermatologic ... percent more than 2014 and up 27 percent since 2012. , The results of ... – including another annual increase in skin cancer treatments and the growing popularity of ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... -- Progra m m e ... , s mosquito in Cayman Islands ... by 96 %   Oxitec and the Cayman Islands ... Aedes aegypti, the dangerous mosquito that spreads dengue, Zika and chikungunya, ... Grand Cayman .  MRCU, a global leader in mosquito control, is planning ...
(Date:5/5/2016)... Research and Markets has announced the addition of ...  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Emission Tomography (PET) scanner and cyclotron install base in ... the current known number of PET scanners and cyclotrons ... also contains a detailed breakdown of this equipment by ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... Markets has announced the addition of the  ... Highlights - 2016"  report to their ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The latest ... Landscape Highlights - 2016, provides comprehensive ...
Breaking Medicine Technology: